Impact of Helicobacter pylori Infection on the efficacy of immune checkpoint inhibitors in gastric cancer: A multicenter retrospective study (KINGCA Week 2026) - Oct 11, 2026 - Abstract #PP-091; Pres time: Sep 18, 2026; 04:20 PM - 05:40 PM; Location: Sapphire 3+4; " This multicenter retrospective study included patients with advanced gastric cancer treated with nivolumab or pembrolizumab at five tertiary centers in the Republic of Korea. In this multicenter cohort of Korean patients with advanced gastric cancer treated with ICIs, H. pylori infection status was not independently associated with survival outcomes. Disease stage, line of therapy, and HER2 status were stronger determinants of prognosis. Larger prospective studies with standardized H. pylori assessment are warranted to validate these findings."
Checkpoint inhibition • IO biomarker • Retrospective data • Gastric Cancer • Infectious Disease • Oncology • Solid Tumor • HER-2
|
|
Dong Chan Joo1; Bokyung Kim2; Hyun Ho Choi3; Na Rae Lim4; Boram Cha6; Ayoung Lee7; Sun-Young Lee8; Jong Yeul Lee9; Joon Sung Kim5
|